載入中
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
前收盤價
US$1.04
−US$0.02 · -1.89%
盤中時間採用ET。市場資料可能有所延遲。
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
日內區間
目前US$1.04
52週區間
目前US$1.04
盤中時間採用ET。市場資料可能有所延遲。
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
日內區間
目前US$1.04
52週區間
目前US$1.04
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 5.8萬 USD | 47.7萬 USD | 135.2萬 USD | 101.5萬 USD |
| 銷貨成本 | 50.5萬 USD | 438.7萬 USD | 772.6萬 USD | 883.4萬 USD | 64萬 USD |
| 毛利 | −50.5萬 USD | −432.9萬 USD | −724.9萬 USD | −748.2萬 USD | 37.5萬 USD |
| 研究與開發 | 496.2萬 USD | 438.7萬 USD | 772.6萬 USD | 883.4萬 USD | 855.8萬 USD |
| 銷售、一般及管理費用 | 331.6萬 USD | — | — | — | 508.7萬 USD |
| 營業費用 | 777.3萬 USD | 367.2萬 USD | 439.5萬 USD | 441.9萬 USD | 1300.5萬 USD |
| 利息收入 | — | — | — | — | 9000 USD |
| 利息支出 | — | — | — | 6000 USD | — |
| 折舊和攤銷 | 50.5萬 USD | 6.7萬 USD | 8.4萬 USD | 8.2萬 USD | 6萬 USD |
| 營業利益 | −827.8萬 USD | −800.1萬 USD | −1164.4萬 USD | −1190.1萬 USD | −1263萬 USD |
| 淨利 | −822.8萬 USD | −794.6萬 USD | −1157.1萬 USD | −1190.7萬 USD | −1262.1萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
